Healthcare -
Medical - Equipment & Services - NYSE - US
$ 223.5
-0.667 %
$ 18.7 B
Market Cap
25.28
P/E
1. INTRINSIC VALUE
Balance Sheet
Laboratory Corporation of America Holdings
| Current Assets | 4.81 B |
| Cash & Short-Term Investments | 1.52 B |
| Receivables | 2.1 B |
| Other Current Assets | 1.19 B |
| Non-Current Assets | 13.6 B |
| Long-Term Investments | 16.3 M |
| PP&E | 3.05 B |
| Other Non-Current Assets | 10.5 B |
| Current Liabilities | 3.33 B |
| Accounts Payable | 876 M |
| Short-Term Debt | 1.19 B |
| Other Current Liabilities | 1.26 B |
| Non-Current Liabilities | 6.98 B |
| Long-Term Debt | 6.08 B |
| Other Non-Current Liabilities | 900 M |
EFFICIENCY
Earnings Waterfall
Laboratory Corporation of America Holdings
| Revenue | 13 B |
| Cost Of Revenue | 9.51 B |
| Gross Profit | 3.5 B |
| Operating Expenses | 2.4 B |
| Operating Income | 1.11 B |
| Other Expenses | 359 M |
| Net Income | 746 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Laboratory Corporation of America Holdings
| Net Income | 746 M |
| Depreciation & Amortization | 644 M |
| Capital Expenditures | -490 M |
| Stock-Based Compensation | 117 M |
| Change in Working Capital | -154 M |
| Others | -195 M |
| Free Cash Flow | 1.1 B |
Wall Street Analysts Price Targets
Laboratory Corporation of America Holdings
Wall Street analysts predict an average 1-year price target for LH of $260 , with forecasts ranging from
a
low of
$240 to a high of $277 .
LH Lowest Price Target
Wall Street Target
240 USD
7.38%
LH Average Price Target
Wall Street Target
260 USD
16.48%
LH Highest Price Target
Wall Street Target
277 USD
23.94%
4. DIVIDEND
ANALYSIS
0.31%
DIVIDEND YIELD
0.72 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Laboratory Corporation of America Holdings
Sold
0-3 MONTHS
4.48 M USD 6
3-6 MONTHS
6.15 M USD 6
6-9 MONTHS
6.81 M USD 4
9-12 MONTHS
1.02 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Here's Why Labcorp (LH) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
- 2 weeks ago
LH Stock to Gain From Launch of HPV and STI Self-Collection Options
Labcorp launches self-collection options for HPV and STI testing in its PSCs.
zacks.com
- 2 weeks ago
Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease
Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C. , April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease.
prnewswire.com
- 2 weeks ago
Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide
New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C. , April 1, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FDA) approved human papillomavirus (HPV) self-collection solution that can help women and their physicians asses the risk of developing cervical cancer.
prnewswire.com
- 2 weeks ago
Labcorp to Announce First Quarter Financial Results on April 29, 2025
BURLINGTON, N.C. , March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025.
prnewswire.com
- 2 weeks ago
Why Labcorp (LH) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
- 1 month ago
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.
zacks.com
- 1 month ago
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
prnewswire.com
- 1 month ago
Should Labcorp Stock Stay in Your Portfolio Right Now?
LH stays on investors' radar owing to its strong focus on high-growth areas and pursuing strategic acquisitions.
zacks.com
- 1 month ago
Here's Why Labcorp (LH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
- 1 month ago
Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors
Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C. , Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM , a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors.
prnewswire.com
- 1 month ago
Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold'
Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive advantages include large scale, diversified business model, strong industry relationships, and operational efficiency, driving strong revenue and margin expansion. Recent strategic initiatives like the Fortrea spin-off, Invitae acquisition, and SYNLAB stake enhance Labcorp's core business and future growth prospects.
seekingalpha.com
- 2 months ago
8. Profile
Summary
Laboratory Corporation of America Holdings LH
COUNTRY
US
INDUSTRY
Medical - Equipment & Services
MARKET CAP
$ 18.7 B
Dividend Yield
0.31%
Description
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Contact
358 South Main Street, Burlington, NC, 27215
https://www.labcorp.com
IPO
Date
March 29, 1990
Employees
60900
Officers
Christin O'Donnell
Vice President of Investor Relations
Dr. Brian J. Caveney J.D., M.D., M.P.H.
EVice President, President of Early Development Research Laboratories and Chief Medical & Scientific Officer
Akinbolade Oyegunwa M.B.A., Ph.D.
Executive Vice President and Chief Information & Technology Officer
Mr. Adam H. Schechter
President, Chief Executive Officer & Chairman
Mr. Mark S. Schroeder
Executive Vice President, President of Diagnostics Laboratories & Chief Operating Officer
Mr. Peter J. Wilkinson
Senior Vice President & Chief Accounting Officer
Ms. Anita Z. Graham
Executive Vice President & Chief Human Resources Officer
Mr. Glenn A. Eisenberg
Executive Vice President & Special Advisor to the Chief Executive Officer
Ms. Julia Wang
Chief Financial Officer & Executive Vice President
Ms. Sandra D. van der Vaart J.D.
Executive Vice President, Chief Legal Officer & Corporate Secretary